Try our mobile app

Switch to company model in "Rising Stars" logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Categories: @vaccine-makers   

Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Website: modernatx.com


  • Bad financial results growth rate -84.3% (average between last period year over year growth for revenue and EBITDA), there is slowdown compared to average historical growth rates (92.3%)
  • Dividend yield for the last twelve months 0.0%
  • Free cash flow yield 37.7% (LTM)
  • Share price is 14.4% higher than minimum and 83.5% lower than maximum for the last 3 years
  • The company is undervalued by EV / LTM EBITDA multiple compared to target level (1.1x vs 6.6x)
  • Fundamental value created in LTM (estimate)
  • For the last 3 months insiders bought company shares on $6.0 mln (0.048% of cap.)

Key Financials (Download financials)

Ticker: MRNA
Share price, USD:  (+0.9%)34.62
year average price 77.62  


year start price 103.85 2024-03-17

max close price 166.61 2024-05-24

min close price 30.27 2025-03-03

current price 34.62 2025-03-16
Common stocks: 397 760 005

Dividend Yield:  0.0%
FCF Yield LTM: 37.7%
EV / LTM EBITDA: 1.1x
EV / Sales: 0.4x
Margin (EBITDA LTM / Revenue): 34.0%

Target EV / EBITDA (hist percentile): 6.6x
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 13 770
Net Debt ($m): -7 996
EV (Enterprise Value): 5 774
EBITDA LTM (млн $): 5 115
EV / LTM EBITDA: 1.1x
Price to Book: 1.2x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2025-03-15fool.com

Down 93%, Is It Finally Time to Buy Moderna?

2025-03-06zacks.com

Here's Why Moderna Stock Soared 16% on Wednesday

2025-03-05investopedia.com

S&P 500 Gains and Losses Today: Moderna Stock Pops as Execs Buy Shares, Express Cancer Vaccine Optimism

2025-03-04fool.com

Coatue's Philippe Laffont Just Bought Shares of This Beaten-Down Growth Stock That Wall Street Predicts Will Soar 80%

2025-03-03globenewswire.com

Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna

2025-02-27marketwatch.com

Moderna's stock stumbles on report HHS is reviewing a $590 million bird-flu-vaccine award

2025-02-25globenewswire.com

CancerVax Announces Successful Tests of its Smart mRNA Technology

2025-02-24zacks.com

Moderna (MRNA) International Revenue Performance Explored

2025-02-21investopedia.com

Moderna and Other Vaccine Stocks Climb Amid Concerns About Coronavirus Study in China

2025-02-21investopedia.com

Moderna and Other Vaccine Stocks Climb After Coronavirus News From China
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol MRNA MRNA MRNA MRNA MRNA MRNA MRNA MRNA MRNA
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-11-07 2024-08-01 2024-05-02 2024-02-23 2023-11-03 2023-08-03 2023-05-04 2023-02-24 2022-11-03
acceptedDate 2024-11-07 16:03:09 2024-08-01 16:02:28 2024-05-02 16:03:11 2024-02-23 16:03:10 2023-11-03 16:02:21 2023-08-03 16:04:10 2023-05-04 16:03:31 2023-02-24 16:03:35 2022-11-03 16:05:50
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
revenue 1 855M 241M 167M 2 813M 1 831M 344M 1 862M 5 084M 3 220M
costOfRevenue 514M 156M 132M 929M 2 241M 731M 792M 1 918M 1 100M
grossProfit 1 341M 85M 35M 1 884M -410M -387M 1 070M 3 166M 2 120M
grossProfitRatio 0.723 0.353 0.21 0.67 -0.224 -1.125 0.575 0.623 0.658
researchAndDevelopmentExpenses 1 137M 1 180M 1 027M 1 406M 1 160M 1 148M 1 131M 1 211M 820M
generalAndAdministrativeExpenses 0 0 0 266M 0 0 0 0 0
sellingAndMarketingExpenses 0 0 0 204M 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 281M 268M 274M 470M 442M 332M 305M 375M 278M
otherExpenses -7M -20M 2M -11M -51M 14M -48M -12M -144M
operatingExpenses 1 411M 1 448M 1 301M 1 878M 1 602M 1 480M 1 436M 1 586M 954M
costAndExpenses 1 925M 1 604M 1 433M 2 807M 3 843M 2 211M 2 228M 3 504M 2 054M
interestIncome 103M 111M 120M 103M 105M 104M 109M 87M 58M
interestExpense 6M 6M 6M 6M 10M 13M -61M 10M 8M
depreciationAndAmortization 52M 41M 36M 43 812 249M 92M 78M 80M 176M
ebitda 79M -1 232M -1 230M 300M -1 763M -1 775M -288M 1 580M 1 342M
ebitdaratio 0.043 -5.485 -7.365 0.107 -0.963 -5.16 -0.155 0.311 0.417
operatingIncome -70M -1 363M -1 266M 6M -2 012M -1 867M -366M 1 580M 1 166M
operatingIncomeRatio -0.038 -5.656 -7.581 0.002 -1.099 -5.427 -0.197 0.311 0.362
totalOtherIncomeExpensesNet 91M 84M 101M -33M -51M 14M 61M 75M 51M
incomeBeforeTax 21M -1 279M -1 165M 70M -1 958M -1 749M -305M 1 655M 1 217M
incomeBeforeTaxRatio 0.011 -5.307 -6.976 0.025 -1.069 -5.084 -0.164 0.326 0.378
incomeTaxExpense 8M 0 10M -147M 1 672M -369M -384M 190M 174M
netIncome 13M -1 279M -1 175M 217M -3 630M -1 380M 79M 1 465M 1 043M
netIncomeRatio 0.007 -5.307 -7.036 0.077 -1.983 -4.012 0.042 0.288 0.324
eps 0.034 -3.33 -3.08 0.57 -9.53 -3.62 0.2 3.81 2.67
epsdiluted 0.033 -3.33 -3.08 0.55 -9.53 -3.62 0.19 3.61 2.53
weightedAverageShsOut 385M 384M 382M 381M 381M 381M 386M 385M 390M
weightedAverageShsOutDil 399M 384M 382M 395M 381M 381M 405M 405M 412M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol MRNA MRNA MRNA MRNA MRNA MRNA MRNA MRNA MRNA
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-11-07 2024-08-01 2024-05-02 2024-02-23 2023-11-03 2023-08-03 2023-05-04 2023-02-24 2022-11-03
acceptedDate 2024-11-07 16:03:09 2024-08-01 16:02:28 2024-05-02 16:03:11 2024-02-23 16:03:10 2023-11-03 16:02:21 2023-08-03 16:04:10 2023-05-04 16:03:31 2023-02-24 16:03:35 2022-11-03 16:05:50
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 1 644M 2 478M 2 068M 2 907M 2 932M 3 801M 3 441M 3 205M 3 027M
shortTermInvestments 5 223M 6 010M 6 472M 5 697M 4 641M 4 658M 5 482M 6 697M 5 321M
cashAndShortTermInvestments 1 644M 8 488M 8 540M 8 604M 7 573M 8 459M 8 923M 9 902M 8 348M
netReceivables 1 564M 163M 387M 1 081M 1 866M 232M 1 113M 1 385M 2 821M
inventory 412M 399M 295M 202M 487M 715M 732M 949M 2 077M
otherCurrentAssets 6 046M 611M 378M 88M 873M 1 193M 6 836M 1 195M 85M
totalCurrentAssets 9 666M 9 661M 9 600M 10 325M 10 799M 10 599M 12 122M 13 431M 14 297M
propertyPlantEquipmentNet 3 165M 2 971M 2 760M 2 658M 2 717M 2 410M 2 135M 2 139M 2 132M
goodwill 52M 52M 52M 52M 52M 52M 52M 0 0
intangibleAssets 41M 42M 43M 44M 45M 46M 48M 0 0
goodwillAndIntangibleAssets 93M 94M 95M 96M 97M 98M 100M 0 0
longTermInvestments 2 335M 2 357M 3 694M 4 743M 5 273M 6 105M 7 442M 8 318M 8 655M
taxAssets 81M 81M 81M 81M -97M 1 480M 1 262M 982M 920M
otherNonCurrentAssets 463M 516M 499M 523M 661M 1 192M 1 064M 988M 52M
totalNonCurrentAssets 6 137M 6 019M 7 129M 8 101M 8 651M 11 285M 12 003M 12 427M 11 759M
otherAssets 0 0 0 0 0 0 0 0 0
totalAssets 15 803M 15 680M 16 729M 18 426M 19 450M 21 884M 24 125M 25 858M 26 056M
accountPayables 373M 279M 183M 520M 494M 310M 389M 487M 330M
shortTermDebt 0 32M 25M 25M 56M 221M 181M 196M 260M
taxPayables 4M 7M 52M 63M 56M 47M 66M 48M 66M
deferredRevenue 379M 702M 559M 568M 1 372M 1 040M 1 219M 2 038M 4 002M
otherCurrentLiabilities 1 445M 1 350M 1 613M 1 902M 2 463M 1 552M 1 710M 2 202M 2 215M
totalCurrentLiabilities 2 201M 2 363M 2 380M 3 015M 4 385M 3 123M 3 499M 4 923M 6 807M
longTermDebt 1 304M 1 244M 1 212M 1 218M 1 272M 947M 927M 1 004M 1 001M
deferredRevenueNonCurrent 0 95M 58M 83M 166M 692M 673M 673M 175M
deferredTaxLiabilitiesNonCurrent 0 0 -58M 0 0 0 0 0 0
otherNonCurrentLiabilities 371M 266M 320M 256M 172M 173M 163M 135M -3 335M
totalNonCurrentLiabilities 1 675M 1 605M 1 532M 1 557M 1 610M 1 812M 1 763M 1 812M 1 257M
otherLiabilities 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 0 1 269M 1 212M 1 243M 1 272M 947M 927M 1 004M 1 261M
totalLiabilities 3 876M 3 968M 3 912M 4 572M 5 995M 4 935M 5 262M 6 735M 8 064M
preferredStock 0 0 0 0 0 0 0 0 0
commonStock 0 0 0 0 0 0 0 0 0
retainedEarnings 11 165M 11 152M 12 431M 13 606M 13 389M 17 019M 18 399M 18 320M 16 855M
accumulatedOtherComprehensiveIncomeLoss 11M -71M -101M -123M -211M -263M -267M -370M -351M
othertotalStockholdersEquity 751M 631M 487M 371M 277M 193M 731M 1 173M 1 488M
totalStockholdersEquity 11 927M 11 712M 12 817M 13 854M 13 455M 16 949M 18 863M 19 123M 17 992M
totalEquity 11 927M 11 712M 12 817M 13 854M 13 455M 16 949M 18 863M 19 123M 17 992M
totalLiabilitiesAndStockholdersEquity 15 803M 15 680M 16 729M 18 426M 19 450M 21 884M 24 125M 25 858M 26 056M
minorityInterest 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 15 803M 15 680M 16 729M 18 426M 19 450M 21 884M 24 125M 25 858M 26 056M
totalInvestments 7 581M 8 367M 10 166M 4 677M 5 273M 6 105M 7 442M 15 015M 13 976M
totalDebt 1 355M 617M 1 237M 1 243M 1 272M 947M 927M 1 200M 1 261M
netDebt -289M -2 478M -831M -1 664M -1 660M -2 854M -2 514M -2 005M -1 766M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Cash Flow Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol MRNA MRNA MRNA MRNA MRNA MRNA MRNA MRNA MRNA
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-11-07 2024-08-01 2024-05-02 2024-02-23 2023-11-03 2023-08-03 2023-05-04 2023-02-24 2022-11-03
acceptedDate 2024-11-07 16:03:09 2024-08-01 16:02:28 2024-05-02 16:03:11 2024-02-23 16:03:10 2023-11-03 16:02:21 2023-08-03 16:04:10 2023-05-04 16:03:31 2023-02-24 16:03:35 2022-11-03 16:05:50
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
netIncome 13M -1 279M -1 175M 217M -3 630M -1 380M 79M 1 465M 1 043M
depreciationAndAmortization 52M 41M 36M 202M 249M 92M 78M 80M 113M
deferredIncomeTax 0 0 0 -106M 1 464M -220M -310M -37M 0
stockBasedCompensation 112M 112M 101M 79M 77M 74M 75M 62M 70M
changeInWorkingCapital 86M -146M 60M 249M 182M 574M -1 144M 626M -1 001M
accountsReceivables -1 401M -26M 755M 974M -1 634M 881M 272M 1 310M -4M
inventory -11M -104M -93M 285M 228M 18M 216M 1 128M -156M
accountsPayables 96M 104M -303M 21M 179M -70M -117M 151M 145M
otherWorkingCapital 1 402M -120M -299M -1 031M 1 409M -255M -1 515M -1 963M -986M
otherNonCashItems -1 829M -2M -197M -19M 58M -55M -3M -534M 27M
netCashProvidedByOperatingActivities -1 566M -1 274M -989M 622M -1 600M -915M -1 225M 1 662M 252M
investmentsInPropertyPlantAndEquipment -151M -182M -196M -220M -140M -234M -113M -92M -89M
acquisitionsNet 0 0 0 3 107M -929M -2 178M -85M 0 0
purchasesOfInvestments -1 251M -846M -2 544M -1 640M -816M -196M -1 108M -2 510M -191M
salesMaturitiesOfInvestments 2 123M 2 677M 2 858M 1 345M 1 745M 2 374M 3 317M 1 559M 1 225M
otherInvestingActivites 0 0 314M -23M 929M 2 178M 0 -5M 0
netCashUsedForInvestingActivites 721M 1 649M 118M -538M 789M 1 944M 2 011M -1 048M 945M
debtRepayment 3M 2M -1 000 000 -124M -65M -56M 0 -77M 0
commonStockIssued 8M 32M 15M 15M 6M 16M 9M 24M 0
commonStockRepurchased 0 0 0 0 1 000 000 -628M -526M -402M -1 006M
dividendsPaid 0 0 0 0 0 -40M 0 0 0
otherFinancingActivites 0 0 15M 15M 59M 40M -25M 17M -35M
netCashUsedProvidedByFinancingActivities 11M 34M 14M -109M -58M -668M -542M -438M -1 041M
effectOfForexChangesOnCash 1 000 000 0 0 0 0 0 0 0 0
netChangeInCash -831M 410M -856M -25M -869M 361M 244M 176M 156M
cashAtEndOfPeriod 1 647M 2 478M 2 068M 2 928M 2 953M 3 822M 3 461M 3 217M 3 041M
cashAtBeginningOfPeriod 2 480M 2 068M 2 924M 2 953M 3 822M 3 461M 3 217M 3 041M 2 885M
operatingCashFlow -1 566M -1 274M -989M 622M -1 600M -915M -1 225M 1 662M 252M
capitalExpenditure -151M -182M -196M -220M -140M -234M -113M -92M -89M
freeCashFlow -1 717M -1 456M -1 185M 402M -1 740M -1 149M -1 338M 1 570M 163M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Earning call transcript

2024 q3
2024-11-07 ET (fiscal 2024 q3)
2024 q2
2024-08-01 ET (fiscal 2024 q2)
2024 q1
2024-05-02 ET (fiscal 2024 q1)
2023 q4
2024-02-22 ET (fiscal 2023 q4)
2023 q3
2023-11-02 ET (fiscal 2023 q3)
2023 q2
2023-08-03 ET (fiscal 2023 q2)
2023 q1
2023-05-04 ET (fiscal 2023 q1)
2022 q4
2023-02-23 ET (fiscal 2022 q4)
2022 q3
2022-11-03 ET (fiscal 2022 q3)
2022 q2
2022-08-03 ET (fiscal 2022 q2)
2022 q1
2022-05-04 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-11-07 11:30 ET
Moderna Reports Third Quarter 2024 Financial Results and Provides Business Updates
2024-11-05 14:05 ET
Carisma Therapeutics to Present New Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma at SITC 2024
2024-10-24 18:25 ET
Moderna Named a Top Employer by Science for Tenth Consecutive Year
2024-10-17 11:05 ET
Moderna to Report Third Quarter 2024 Financial Results on Thursday, November 7, 2024
2024-10-02 11:00 ET
Abbas Hussain Joins Moderna's Board of Directors
2024-10-01 00:00 ET
Moderna and Cenra Healthcare Enter Joint Agreement to Promote Moderna’s mRNA Respiratory Vaccine Portfolio in Taiwan, Including COVID-19 Vaccines
2024-09-30 11:00 ET
Moderna Announces First Participant Dosed in Pivotal Phase 3 Trial of Investigational mRNA Norovirus Vaccine, mRNA-1403
2024-09-17 15:00 ET
Moderna Receives Health Canada Approval For Updated COVID-19 Vaccine Targeting KP.2 Variant Of SARS-COV-2 For Ages Six Months And Older
2024-09-12 10:00 ET
Moderna R&D Day Highlights Progress and Strategic Priorities
2024-09-10 11:30 ET
Carisma and Moderna Expand Collaboration to Develop Two In Vivo CAR-M Therapies for Autoimmune Diseases
2024-09-09 11:00 ET
Moderna’s Canadian Manufacturing Facility Receives Drug Establishment License From Health Canada
2024-09-05 12:00 ET
EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's COVID-19 mRNA Vaccine Targeting the SARS-COV-2 Variant JN.1
2024-09-03 12:30 ET
Moderna Receives Medicines And Healthcare Products Regulatory Agency (MHRA) Authorization For Updated COVID-19 Vaccine Targeting SARS-COV-2 Variant JN.1
2024-09-02 11:00 ET
Taiwan Food & Drug Administration Approves Moderna’s COVID-19 mRNA Vaccine Targeting the SARS-COV-2 Variant JN.1
2024-08-23 11:00 ET
Moderna Receives European Commission Approval for RSV Vaccine mRESVIA(R)
2024-08-22 11:00 ET
Moderna to Host Investor Event - R&D Day and Business Updates
2024-08-22 04:00 ET
Moderna Receives U.S. FDA Approval for Updated COVID-19 Vaccine Targeting KP.2 Variant of SARS-CoV-2
2024-08-01 10:30 ET
Moderna Reports Second Quarter 2024 Financial Results and Provides Business Updates
2024-07-23 11:00 ET
David Rubenstein Joins Moderna's Board of Directors
2024-07-10 11:00 ET
Moderna to Report Second Quarter 2024 Financial Results on Thursday, August 1, 2024
2024-07-08 23:00 ET
Moderna And Mitsubishi Tanabe Pharma Corporation Enter Joint Agreement to Promote Moderna’s mRNA Respiratory Vaccine Portfolio in Japan, Including COVID-19 Vaccines
2024-07-02 11:30 ET
Moderna Receives Project Award through BARDA's Rapid Response Partnership Vehicle Consortium to Accelerate Development of mRNA-based Pandemic Influenza Vaccine
2024-06-28 11:00 ET
EMA Committee For Medicinal Products For Human Use Adopts Positive Opinion Recommending Marketing Authorization Of Moderna’s RSV Vaccine, mRESVIA(R)
2024-06-13 11:00 ET
Moderna Announces Positive Phase 3 Efficacy Data for mRNA-1283, the Company’s Next Generation COVID-19 Vaccine
2024-06-10 10:30 ET
Moderna Announces Positive Phase 3 Data for Combination Vaccine Against Influenza and COVID-19
2024-06-07 14:30 ET
Moderna Files FDA Application for the JN.1 Targeting COVID-19 Vaccine
2024-06-06 11:00 ET
Moderna's Investigational Therapeutic for Methylmalonic Acidemia (mRNA-3705) Selected by U.S. Food & Drug Administration for START Pilot Program
2024-05-31 14:58 ET
Moderna Receives U.S. FDA Approval for RSV Vaccine mRESVIA(R)
2024-05-22 11:00 ET
Moderna Announces Data to be Presented at 2024 ASCO Annual Meeting
2024-05-13 11:00 ET
Moderna to Present at Upcoming Conferences in May/June 2024
2024-05-10 11:00 ET
Moderna Announces Update on Investigational RSV Vaccine
2024-05-02 10:30 ET
Moderna Reports First Quarter 2024 Financial Results and Provides Business Updates
2024-05-01 12:30 ET
3 Trends In Healthcare Guided By AI And The Companies Behind The Innovation
2024-04-25 11:00 ET
Moderna To Present Respiratory & Cytomegalovirus Research at the ESCMID Global Congress
2024-04-24 12:00 ET
Moderna and OpenAI Collaborate To Advance mRNA Medicine
2024-04-22 11:00 ET
Moderna Announces Contract with Brazil to Supply 12.5 million COVID-19 Vaccines as Part of National Vaccination Campaign
2024-04-17 11:00 ET
Moderna to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024
2024-04-03 15:00 ET
Phase 1/2 Interim Data on Moderna’s mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia, Published in Nature
2024-03-27 12:50 ET
CARsgen Announced 2023 Annual Results
2024-03-27 10:30 ET
Moderna Advances Multiple Vaccine Programs to Late-Stage Clinical Trials
2024-03-26 11:00 ET
Moderna Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine
2024-02-29 12:00 ET
Moderna to Host Fifth Annual Investor Event For Vaccines and Business Updates on March 27, 2024
2024-02-28 12:00 ET
Moderna to Present at Upcoming Investor Conferences in March 2024
2024-02-22 11:30 ET
Moderna Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Updates
2024-02-07 05:00 ET
Moderna Chief Executive Officer Stéphane Bancel Elected to National Academy of Engineering
2024-02-01 12:00 ET
Moderna to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 22, 2024
2024-01-31 22:45 ET
Moderna Named to Fortune's List of World's Most Admired Companies
2024-01-08 12:00 ET
Moderna Provides Business and Pipeline Updates at 42nd Annual J.P. Morgan Healthcare Conference
2023-12-20 21:05 ET
Moderna to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2023-12-14 23:00 ET
Moderna Announces New England Journal of Medicine Publication of Pivotal Phase 3 Clinical Safety and Efficacy Data For MRNA-1345, The Company’s Investigational Respiratory Syncytial Virus (RSV) Vaccine
2023-12-14 12:00 ET
First In Vivo CAR-M Lead Candidate Nominated Under Carisma-Moderna Collaboration
2023-12-14 11:30 ET
Moderna And Merck Announce mRNA-4157 (V940) In Combination with Keytruda(R) (Pembrolizumab) Demonstrated Continued Improvement in Recurrence-Free Survival and Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following ...
2023-12-12 13:00 ET
Moderna Announces Changes to Commercial Organization to Prepare for Multiple Product Launches in 2024 and 2025
2023-12-11 11:45 ET
Merck and Moderna Initiate INTerpath-002, a Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) for Adjuvant Treatment of Patients with Certain Types of Resected Non-Small Cell Lung Cancer
2023-12-07 12:00 ET
Moderna Reviews its Environmental, Social and Governance (ESG) Progress and Ambitions at Second ESG Investor Event
2023-11-14 12:00 ET
Moderna to Host Second Environmental, Social and Governance (ESG) Investor Event on December 7th, 2023
2023-11-08 21:15 ET
Moderna to Present at Upcoming Conferences in November 2023
2023-11-08 12:00 ET
Moderna Highlights its Digital and AI Strategy and Progress at Second Digital Investor Event
2023-11-07 13:00 ET
Moderna Tops BioSpace’s Best Places to Work Ranking for Third Consecutive Year
2023-11-02 10:30 ET
Moderna Reports Third Quarter 2023 Financial Results and Provides Business Updates
2023-10-30 07:00 ET
CEPI y Moderna aprovechan la tecnología ARNm para avanzar en la Misión de los 100 días
2023-10-26 18:45 ET
Moderna Named a Top Employer by Science for Ninth Consecutive Year
2023-10-24 11:00 ET
Moderna Announces First Participant Dosed in Phase 3 Study of mRNA-1083, a Combination Vaccine Against Influenza and COVID-19
2023-10-24 10:30 ET
Caris Life Sciences and Moderna Announce Multi-Year Strategic Partnership to Advance mRNA-Based Oncology Therapeutics
2023-10-19 11:45 ET
Moderna to Host Second Digital Investor Event on November 8th, 2023
2023-10-12 11:00 ET
Moderna to Report Third Quarter 2023 Financial Results on Thursday, November 2, 2023
2023-10-04 11:00 ET
Moderna Announces Positive Phase 1/2 Data from mRNA-1083, the Company's Combination Vaccine Against Influenza and COVID-19
2023-09-29 23:37 ET
Moderna Recommends Shareholders Reject Amended “Mini-Tender” Offer by TRC Capital Investment Corporation
2023-09-14 14:15 ET
EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna’s Updated Covid-19 Vaccine in The European Union
2023-09-13 10:30 ET
Moderna Expands the Field of mRNA Medicine with Positive Clinical Results Across Cancer, Rare Disease, and Infectious Disease
2023-09-11 17:53 ET
Moderna Receives U.S. FDA Approval for Updated COVID-19 Vaccine
2023-09-11 11:00 ET
Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics
2023-09-08 20:37 ET
Moderna Recommends Shareholders Reject “Mini-Tender” Offer by TRC Capital Investment Corporation
2023-09-06 20:30 ET
Moderna to Participate at Morgan Stanley 21st Annual Global Healthcare Conference
2023-09-06 11:00 ET
Moderna Clinical Trial Data Confirm Its Updated Covid-19 Vaccine Generates Strong Immune Response in Humans Against BA.2.86
2023-08-30 11:00 ET
Moderna to Host Investor Event - R&D Day and Business Updates
2023-08-22 11:30 ET
CARsgen Announced 2023 Interim Results
2023-08-17 20:15 ET
Moderna Clinical Trial Data Confirm Its Updated COVID-19 Vaccine Generates Robust Immune Response in Humans Against Widely Circulating Variants
2023-08-14 14:00 ET
UMass Chan Medical School announces enrollment in study to examine impact of cytomegalovirus (CMV) transmission in early education settings
2023-08-03 10:30 ET
Moderna Reports Second Quarter 2023 Financial Results and Provides Business Updates
2023-07-26 10:45 ET
Merck and Moderna Initiate Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) for Adjuvant Treatment of Patients with Resected High-Risk (Stage IIB-IV) Melanoma
2023-07-13 11:00 ET
Moderna to Report Second Quarter 2023 Financial Results on Thursday, August 3, 2023
2023-07-05 11:00 ET
Moderna Announces Global Regulatory Submissions For Its Respiratory Syncytial Virus (RSV) Vaccine, MRNA-1345
2023-07-03 05:00 ET
Moderna Submits Regulatory Application to the European Medicines Agency for Its Updated COVID-19 Vaccine
2023-06-22 20:05 ET
Moderna Files for FDA Authorization of Its Updated COVID-19 Vaccine
2023-06-05 12:00 ET
Moderna and Merck Announce mRNA-4157 (V940) in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Mela...
2023-06-01 20:05 ET
Moderna to Present at Upcoming Conferences in June 2023
2023-05-30 12:00 ET
Moderna Announces Phase 2 Data on mRNA-4157 (V940), an Investigational Individualized Neoantigen Therapy, to be Presented at the 2023 ASCO Annual Meeting
2023-05-19 11:00 ET
Phase 1/2 Interim Data on Moderna's mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia (PA), Presented at the 2023 ASGCT Annual Meeting
2023-05-04 10:30 ET
Moderna Reports First Quarter 2023 Financial Results and Provides Business Updates
2023-05-03 20:05 ET
Moderna Announces Phase 1/2 Data on mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia (PA) to be Presented at the 2023 ASGCT Annual Meeting
2023-05-02 21:15 ET
Moderna Announces Establishment of an Enterprise Solutions Hub and Commercial Operations in The Philippines
2023-04-20 20:05 ET
Moderna to Report First Quarter 2023 Financial Results on Thursday, May 4, 2023
2023-04-20 11:30 ET
Moderna and IBM to Explore Quantum Computing and Generative AI for mRNA Science
2023-04-16 15:00 ET
Moderna and Merck Announce mRNA-4157 (V940), an Investigational Individualized Neoantigen Therapy, in Combination with KEYTRUDA(R) (Pembrolizumab), Demonstrated Superior Recurrence-Free Survival in Patients with High-Risk Stage III/IV Melanoma Followi...
2023-04-11 11:00 ET
Moderna Announces Clinical and Program Updates at 4th Vaccines Day
2023-04-06 21:00 ET
MRNA-4157/V940, an Investigational Personalized MRNA Cancer Vaccine, in Combination With Keytruda(R) (Pembrolizumab), Receives Prime Scheme Designation From the European Medicines Agency for Adjuvant Treatment of Patients With High-Risk Stage III/IV M...
2023-03-30 11:00 ET
Moderna Finalizes Agreement with the Government of the Republic of Kenya to Establish an mRNA Manufacturing Facility
2023-03-30 09:00 ET
Gandeeva and Moderna Enter into Cryo-EM Research Collaboration to Explore Protein Surface Structure at Atomic Resolution
2023-03-24 11:30 ET
Moderna to Host Fourth Annual Virtual Vaccines Day on April 11, 2023
2023-03-23 11:02 ET
Moderna and Generation Bio Announce Strategic Collaboration to Develop Non-Viral Genetic Medicines
2023-03-23 11:00 ET
Moderna and Generation Bio Announce Strategic Collaboration to Develop Non-Viral Genetic Medicines
2023-03-22 06:00 ET
BenevolentAI Strengthens its Board of Directors with the Appointment of Digital Innovation Expert Marcello Damiani
2023-03-14 21:40 ET
Moderna Announces Phase 2 Data on mRNA-4157/V940, an Investigational mRNA Personalized Cancer Vaccine, to be Presented at the 2023 AACR Annual Meeting
2023-03-10 16:00 ET
Moderna Outlines Commitment to Corporate Growth and Announces U.S. Expansion in 2023
2023-02-28 12:30 ET
Moderna to Present at Cowen's 43rd Annual Health Care Conference
2023-02-23 12:00 ET
Moderna Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Updates
2023-02-22 21:05 ET
Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination With KEYTRUDA(R) (pembrolizumab), was Granted Breakthrough Therapy Designation by the FDA for Adjuvant Treatment of Patients With High-Risk ...
2023-02-22 12:00 ET
Moderna And Life Edit Therapeutics Enter Strategic Collaboration to Accelerate the Development of Novel In Vivo Gene Editing Therapies
2023-02-17 16:00 ET
Health Canada Authorizes Moderna's Omicron-Targeting Bivalent COVID-19 Vaccine in Children & Adolescents (6-17 Years)
2023-02-16 21:05 ET
Moderna Announces Interim Phase 3 Safety and Immunogenicity Results for mRNA-1010, a Seasonal Influenza Vaccine Candidate
2023-02-03 13:45 ET
Personalis and Moderna Sign New Agreement to Leverage NeXT Platform™ in Personalized mRNA Cancer Vaccine Clinical Trials
2023-02-02 12:00 ET
Moderna to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, February 23, 2023
2023-01-30 12:15 ET
Moderna Granted FDA Breakthrough Therapy Designation for mRNA-1345, An Investigational Respiratory Syncytial Virus (RSV) Vaccine Candidate
2023-01-17 21:05 ET
Moderna Announces mRNA-1345, an Investigational Respiratory Syncytial Virus (RSV) Vaccine, Has Met Primary Efficacy Endpoints in Phase 3 Trial in Older Adults
2023-01-09 12:00 ET
Moderna Announces Advances Across mRNA Pipeline and Provides Business Update
2023-01-05 21:05 ET
CytomX and Moderna Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics
2023-01-05 21:05 ET
Moderna and CytomX Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics
2023-01-04 12:00 ET
Moderna to Acquire OriCiro Genomics
2023-01-03 12:00 ET
Moderna to Provide Business and Pipeline Updates at the 2023 J.P. Morgan Healthcare Conference
2022-12-22 00:05 ET
Moderna Finalizes Strategic Partnership with UK Government
2022-12-20 12:42 ET
Chantal Friebertshäuser Joins Moderna as Senior Vice President, Commercial
2022-12-16 12:30 ET
EMA Committee for Medicinal Products for Human Use (CHMP) Recommends the Use of Moderna’s BA.1 Targeting Bivalent COVID-19 Booster in Children (6-11 Years) In the European Union
2022-12-13 12:00 ET
Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination with KEYTRUDA(R) (pembrolizumab), Met Primary Efficacy Endpoint in Phase 2b KEYNOTE-942 Trial
2022-12-08 15:10 ET
Moderna Receives FDA Emergency Use Authorization for Omicron-Targeting Bivalent COVID-19 Booster Vaccine in Children 6 Months Through 5 Years of Age
2022-12-07 21:05 ET
Brad Miller Joins Moderna as Chief Information Officer
2022-11-29 13:00 ET
Moderna to Present at the Piper Sandler 34th Annual Healthcare Conference
2022-11-17 13:10 ET
David Jiménez Joins Moderna As U.S. General Manager
2022-11-16 21:30 ET
Moderna Tops BioSpace's Best Places to Work Ranking for Second Consecutive Year
2022-11-14 12:00 ET
Moderna's BA.4/BA.5 Targeting Bivalent Booster, mRNA-1273.222, Meets Primary Endpoint of Superiority Against Omicron Variants Compared to Booster Dose of mRNA-1273 in Phase 2/3 Clinical Trial
2022-11-11 01:03 ET
Harbour BioMed Enters into a License and Collaboration Agreement with Moderna
2022-11-10 12:35 ET
Moderna Shares Environmental, Social and Governance Highlights at First ESG Day
2022-11-09 13:00 ET
Moderna to Present at the Jefferies 2022 London Healthcare Conference
2022-11-04 21:00 ET
Moderna Receives Health Canada Authorization for Second Omicron-Targeting Bivalent Booster
2022-11-03 11:00 ET
Moderna Reports Third Quarter 2022 Financial Results and Provides Business Updates
2022-11-01 05:30 ET
Ministry of Health, Labour and Welfare in Japan Approves Partial Change to a New Drug Authorization for Moderna's Omicron-Targeting Bivalent Booster COVID-19 Vaccine, mRNA-1273.222
2022-10-27 20:05 ET
Moderna to Host First Environmental, Social and Governance (ESG) Day on November 10, 2022
2022-10-27 18:50 ET
Moderna Named a Top Employer by Science for Eighth Consecutive Year
2022-10-27 13:50 ET
A New BioTech Research Race Is Focused On Improving Life For MS Patients
2022-10-19 17:00 ET
EMA Committee For Medicinal Products For Human Use Adopts Positive Opinion Recommending Authorization Of Moderna's Omicron BA.4-BA.5 Targeting Bivalent Covid-19 Vaccine In The European Union
2022-10-19 16:30 ET
EMA Committee for Medicinal Products for Human Use Issues Positive Opinion Recommending Authorization for the Use of Spikevax (mRNA-1273) in Children 6 Months - 5 Years in the European Union
2022-10-19 12:00 ET
90-Day Analysis Shows Moderna’s Omicron BA.1-Targeting Bivalent Vaccine, mRNA-1273.214, Demonstrates Superior Antibody Response as Fourth Booster Compared to Spikevax Prototype Booster
2022-10-17 10:00 ET
Moderna Announces Update to 2022 Supply Agreement with Gavi that Secures Access to Updated Variant-Specific COVID-19 Vaccines for Low-and-Middle Income Countries
2022-10-13 12:00 ET
Moderna to Report Third Quarter 2022 Financial Results on Thursday, November 3, 2022
2022-10-12 14:40 ET
Moderna Receives FDA Authorization for Emergency Use of Omicron-Targeting Bivalent COVID-19 Booster Vaccine for Children and Adolescents 6 to 17 Years of Age
2022-10-12 11:15 ET
Merck and Moderna Announce Exercise of Option by Merck for Joint Development and Commercialization of Investigational Personalized Cancer Vaccine
2022-10-12 11:00 ET
Moderna exercises option to license proprietary targeting technology from Autolus
2022-09-29 12:00 ET
Moderna Creates New Executive Committee Role Ahead of New Product Launches
2022-09-28 08:50 ET
European Medicines Agency Accepts Moderna's Conditional Marketing Authorization Filing for its Omicron BA.4/BA.5 Targeting Bivalent COVID-19 Vaccine
2022-09-12 11:00 ET
Ministry Of Health, Labour and Welfare in Japan Approves Partial Change to a New Drug Authorization for Moderna's Omicron-Targeting Bivalent Booster COVID-19 Vaccine, mRNA-1273.214
2022-09-08 11:00 ET
Moderna Reviews Clinical Trial Programs Across Portfolio at 2022 R&D Day
2022-09-06 20:05 ET
Moderna to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
2022-09-01 15:00 ET
Health Canada Authorizes Moderna's Omicron-Targeting Bivalent COVID-19 Booster Vaccine
2022-09-01 13:00 ET
EMA Committee for Medicinal Products for Human Use (CHMP) Adopts Positive Opinion Recommending Authorization for the Use of Moderna's Omicron-Targeting Bivalent Booster in the European Union
2022-08-31 14:25 ET
Moderna Receives FDA Authorization for Emergency Use of Omicron-Targeting Bivalent COVID-19 Booster Vaccine for Adults 18 Years and Older
2022-08-30 05:00 ET
Therapeutic Goods Administration Provisionally Approves Moderna’s Omicron-Containing Bivalent Booster Candidate, MRNA-1273.214, For Australia
2022-08-29 11:00 ET
Moderna to Host R&D Day on Thursday, September 8, 2022
2022-08-29 10:10 ET
Swissmedic Authorizes Moderna’s Omicron-Targeting Bivalent Booster Candidate, MRNA-1273.214
2022-08-26 12:00 ET
Moderna Sues Pfizer and BioNTech for Infringing Patents Central to Moderna's Innovative mRNA Technology Platform
2022-08-23 20:05 ET
Moderna Completes Application To U.S. Food And Drug Administration For Emergency Use Authorization Of Omicron-Targeting Bivalent Covid-19 Booster Vaccine, mRNA-1273.222
2022-08-22 11:00 ET
Moderna to Supply 12 Million Doses of Omicron-Containing Bivalent COVID-19 Booster Vaccines to the Government of Canada
2022-08-17 12:00 ET
James Mock Joins Moderna as Chief Financial Officer
2022-08-15 11:00 ET
Medicines and Healthcare Products Regulatory Agency (MHRA) Authorizes Moderna's Omicron-Containing Bivalent Booster in the UK
2022-08-08 04:00 ET
Moderna And the European Commission (EC) Amend Covid-19 Vaccine Agreement to Supply Omicron-Containing Bivalent Candidates; EC Purchases Additional 15 million Doses
2022-08-03 11:00 ET
Moderna Reports Second Quarter 2022 Financial Results and Provides Business Updates
2022-07-29 12:00 ET
Moderna Announces New Supply Contract With The U.S. Government For An Initial 66 Million Doses Of A Moderna Bivalent Covid-19 Booster Vaccine With Options For U.S. Government To Purchase Up To An Additional 234 Million Doses
2022-07-22 12:00 ET
EMA Committee for Medicinal Products for Human Use (CHMP) Recommends Use of the Moderna COVID-19 Booster in Adolescents (12-17 Years) in the European Union
2022-07-19 03:00 ET
Therapeutic Goods Administration Grants Provisional Approval for Moderna’s COVID-19 Vaccine in Children Aged Six Months to Five Years
2022-07-14 15:30 ET
Health Canada Authorizes Moderna's COVID-19 Vaccine in Young Children (6 Months-5 Years)
2022-07-13 12:00 ET
Moderna to Report First Quarter Financial Results on Wednesday, August 3, 2022
2022-07-12 11:00 ET
Moderna Announces First Participant Dosed in a Phase 1 Trial of its Nipah Virus mRNA Vaccine, mRNA-1215
2022-07-11 12:00 ET
Moderna's Omicron-Containing Bivalent Booster Candidate, mRNA-1273.214, Demonstrates Significantly Higher Neutralizing Antibody Response Against Omicron Subvariants BA.4/5 Compared To Currently Authorized Booster
2022-06-22 11:03 ET
Moderna Announces Bivalent Booster mRNA-1273.214 Demonstrates Potent Neutralizing Antibody Response Against Omicron Subvariants BA.4 And BA.5
2022-06-21 23:05 ET
Moderna Announces Plan to Bring mRNA Innovation to the United Kingdom
2022-06-17 13:05 ET
Moderna Receives FDA Authorization for Emergency Use of Its COVID-19 Vaccine for Children 6 Months of Age and Older
2022-06-08 11:00 ET
Moderna Announces Omicron-Containing Bivalent Booster Candidate mRNA-1273.214 Demonstrates Superior Antibody Response Against Omicron
2022-06-07 11:00 ET
Moderna Announces First Participants Dosed in Phase 3 Study of Seasonal Influenza Vaccine Candidate (mRNA-1010)
2022-06-02 10:30 ET
Moderna and the European Commission Agree on Amendment to COVID-19 Vaccine Supply Agreement
2022-06-01 11:57 ET
Moderna to Present at Upcoming Conferences in June 2022
2022-05-31 07:56 ET
Takeda and Moderna Announce Plans to Transfer Marketing Authorization for Spikevax™ COVID-19 Vaccine in Japan to Moderna
2022-05-31 07:40 ET
Moderna and Takeda Announce Plans to Transfer Marketing Authorization for Spikevax(TM) COVID-19 Vaccine in Japan to Moderna
2022-05-18 19:55 ET
Moderna to Present at the UBS 2022 Global Healthcare Conference
2022-05-18 11:00 ET
IAVI and Moderna Launch First-in-Africa Clinical Trial of mRNA HIV Vaccine Development Program
2022-05-17 11:00 ET
Moderna Announces Advancements in mRNA Platform Science for Application Across Multiple Diseases at Science and Technology Day
2022-05-11 12:00 ET
Departure of Jorge Gomez and Continuation of David Meline as Chief Financial Officer
2022-05-09 11:00 ET
Moderna to Host Annual Science and Technology Day on May 17, 2022
2022-05-04 10:52 ET
Moderna Reports First Quarter 2022 Financial Results and Provides Business Updates
2022-04-29 15:30 ET
Moderna Files to Expand Conditional Marketing Authorization for Its COVID-19 Vaccine to Include Children Six Months to Under Six Years in The European Union
2022-04-29 14:05 ET
Moderna Finalizes Plan for Long-Term Strategic Partnership with The Government of Canada
2022-04-28 11:10 ET
Moderna Files for Authorization of Its COVID-19 Vaccine in Young Children Six Months to Under Six Years of Age
2022-04-27 12:55 ET
Arpa Garay Joins Moderna as Chief Commercial Officer
2022-04-19 10:50 ET
Moderna Announces Clinical Update on Bivalent COVID-19 Booster Platform
2022-04-13 12:00 ET
Moderna to Report First Quarter Financial Results on Wednesday, May 4, 2022
2022-04-11 13:00 ET
Jorge Gomez Joins Moderna as Chief Financial Officer
2022-04-11 12:00 ET
Moderna Announces First Participants Dosed in Phase 1/2 Study with mRNA-1020 and mRNA-1030 Seasonal Influenza Vaccine Candidates
2022-04-07 11:00 ET
IAVI and Moderna Partner to Tackle Broad Global Health Priorities Using mRNA for Vaccines and Antibodies
2022-04-04 13:00 ET
Moderna Launches New Charitable Foundation
2022-03-29 14:40 ET
Moderna Receives FDA Approval for Emergency Use Authorization of 2nd Booster Dose of Its COVID-19 Vaccine, mRNA-1273
2022-03-24 11:00 ET
Moderna Announces Clinical and Program Updates at 3rd Annual Vaccines Day
2022-03-23 23:32 ET
Moderna Finalizes Strategic Partnership with Australian Government
2022-03-23 12:00 ET
Moderna Announces its COVID-19 Vaccine Phase 2/3 Study in Children 6 Months to Under 6 Years Has Successfully Met Its Primary Endpoint
2022-03-22 14:00 ET
UMass Chan Medical School announces research collaboration with Moderna to examine impact of Cytomegalovirus (CMV) in young children
2022-03-22 11:20 ET
Moderna Announces New Development Programs Ahead of 3rd Annual Vaccines Day
2022-03-21 06:00 ET
Moderna Announces New Supply Agreement for 2023 with Switzerland for Additional Seven Million Doses of Moderna's COVID-19 Booster Vaccine
2022-03-18 01:15 ET
Moderna Submits Amendment to the Emergency Use Authorization for an Additional Booster Dose of its COVID-19 Vaccine in the U.S.
2022-03-17 15:00 ET
Health Canada Authorizes Moderna's COVID-19 Vaccine in Children (6-11 Years)
2022-03-16 12:00 ET
Moderna and the Japanese Government Reach an Agreement to Supply Japan with Additional 70 Million Doses of Moderna's COVID-19 Booster Vaccine
2022-03-14 13:15 ET
Moderna Announces First Participant Dosed in Phase 1 Study of its HIV Trimer mRNA Vaccine
2022-03-10 13:23 ET
Moderna Announces First Participant Dosed in Phase 2 Study of Omicron-Specific Bivalent Booster Candidate
2022-03-10 13:00 ET
Moderna to Host Third Annual Virtual Vaccines Day on March 24, 2022
2022-03-08 00:00 ET
Moderna Announces Its Global Public Health Strategy
2022-03-07 13:25 ET
Moderna Announces Memorandum of Understanding with the Government of the Republic of Kenya to Establish its First mRNA Manufacturing Facility in Africa
2022-03-03 14:25 ET
Moderna Announces Establishment of Enterprise Solutions Hub in Atlanta, Georgia
2022-03-02 13:00 ET
Moderna to Present at Upcoming Conferences in March 2022
2022-02-28 11:02 ET
Arbutus Biopharma and Genevant Sciences File Patent Infringement Lawsuit Against Moderna
2022-02-28 11:01 ET
Genevant Sciences and Arbutus Biopharma File Patent Infringement Lawsuit Against Moderna
2022-02-24 15:25 ET
EMA Committee for Medicinal Products for Human Use (CHMP) Adopts Positive Opinion Recommending Authorization for The Use of The Moderna Covid-19 Vaccine in Children (6-11 Years) In the European Union
2022-02-24 11:57 ET
Moderna Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Business Updates
2022-02-23 13:00 ET
Moderna and Thermo Fisher Scientific Announce Long-Term Strategic Collaboration
2022-02-22 22:15 ET
Moderna Expands Global Footprint Through Commercial Partnership with Adium in Latin America
2022-02-22 13:00 ET
Moderna Initiates Phase 3 Portion of Pivotal Trial for mRNA Respiratory Syncytial Virus (RSV) Vaccine Candidate, Following Independent Safety Review of Interim Data
2022-02-18 13:00 ET
Moderna Expands Its mRNA Pipeline with Three New Development Programs
2022-02-16 23:30 ET
Therapeutic Goods Administration of Australia Authorizes Moderna's Covid-19 Vaccine in Children (6-11 Years)
2022-02-16 23:01 ET
Moderna Announces Plan to Expand Commercial Footprint in Europe Across Six Additional Countries
2022-02-16 07:05 ET
Moderna and ROVI Expand Long-term Collaboration for the Manufacture of MRNA Medicines Over the Next Ten Years
2022-02-15 23:00 ET
Moderna Announces Plan to Expand Footprint in Asia with Four Additional Subsidiaries
2022-02-14 15:00 ET
Javara Contributes to RSV Prevention Vaccine Trial in Collaboration with Privia Health and Moderna
2022-02-09 20:05 ET
Moderna Chief Technical Operations and Quality Officer Juan Andres Elected to National Academy of Engineering
2022-02-08 16:10 ET
Moderna Announces New Supply Agreement with Colombia for Additional 10.8 Million Doses of Moderna's COVID-19 Vaccine
2022-02-03 13:00 ET
Moderna to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, February 24, 2022
2022-01-31 16:05 ET
Moderna Receives Full U.S. FDA Approval for COVID-19 Vaccine Spikevax
2022-01-27 14:00 ET
IAVI and Moderna Launch Trial of HIV Vaccine Antigens Delivered Through mRNA Technology
2022-01-26 22:18 ET
Moderna Announces First Participant Dosed in Phase 2 Study of Omicron-Specific Booster Candidate and Publication of Data on Booster Durability Against Omicron Variant
2022-01-10 12:00 ET
Moderna Announces Advances Across Its Industry-Leading mRNA Pipeline and Provides Business Update
2022-01-10 11:30 ET
Moderna and Carisma Establish Collaboration to Develop in vivo Engineered Chimeric Antigen Receptor Monocytes (CAR-M) for Oncology
2022-01-10 11:30 ET
Moderna and Carisma Establish Collaboration to Develop in vivo Engineered Chimeric Antigen Receptor Monocytes (CAR-M) for Oncology
2022-01-05 12:00 ET
Moderna Announces First Participant Dosed in Phase 1 Study of its mRNA Epstein-Barr Virus (EBV) Vaccine
2022-01-04 21:01 ET
Moderna to Present at the Goldman Sachs 14th Annual Healthcare CEOs Unscripted Conference
2022-01-03 15:30 ET
Moderna to Provide Business and Pipeline Updates at the 2022 J.P. Morgan Healthcare Conference
2021-12-27 22:00 ET
Moderna Announces Supply Agreement with South Korea for Additional 20 Million Doses of Moderna’s COVID-19 Vaccine or Updated Booster Candidate in 2022
2021-12-27 14:20 ET
Moderna Announces Switzerland Exercises its Option to Purchase Seven Million Additional Doses of Moderna's COVID-19 Booster Vaccine in 2022
2021-12-20 10:00 ET
Moderna Announces Preliminary Booster Data and Updates Strategy to Address Omicron Variant
2021-12-14 05:34 ET
Moderna COVID-19 Vaccine Manufactured in Korea by Samsung Biologics Receives Marketing Authorization from Ministry of Food and Drug Safety of Korea
2021-12-13 23:00 ET
Moderna and Australia Announce Collaboration to Bring mRNA Manufacturing to Australia
2021-12-10 14:00 ET
Moderna Announces Additional 20 Million Doses of COVID-19 Vaccine to COVAX for Supply in 2021 and New Additional Supply Agreement for 2022
2021-12-10 12:00 ET
Moderna Announces Positive Interim Phase 1 Data for mRNA Flu Vaccine and Provides Program Update
2021-12-09 21:44 ET
Moderna to Host Conference Call on Phase 1 Interim Analysis for mRNA Flu Vaccine on Friday, December 10
2021-12-09 14:00 ET
Moderna Launches AI Academy in Partnership with Carnegie Mellon University
2021-12-02 02:28 ET
Moderna Announces Supply Agreement with the UK for Additional 60 Million Doses of Moderna’s COVID-19 Vaccine in 2022 and 2023
2021-11-26 20:31 ET
Moderna Announces Strategy to Address Omicron (B.1.1.529) SARS-CoV-2 Variant
2021-11-22 13:30 ET
Moderna to Present at Upcoming Investor Conferences in December 2021
2021-11-19 21:13 ET
U.S. CDC Advisory Committee on Immunization Practices Recommends Booster Vaccination with Moderna’s COVID-19 Vaccine
2021-11-19 13:07 ET
Moderna Announces FDA Authorization of Booster Dose of COVID-19 Vaccine in the U.S. for Adults 18 Years and Older
2021-11-18 12:00 ET
Moderna Announces First Participant Dosed in Phase 2/3 Study of its mRNA Respiratory Syncytial Virus (RSV) Vaccine
2021-11-17 13:45 ET
Moderna Tops BioSpace’s 2022 Best Places to Work Ranking in Large Employer Category
2021-11-17 13:14 ET
Moderna Files for Authorization of its COVID-19 Vaccine with Health Canada to Include Children Ages 6-11 Years
2021-11-16 12:24 ET
Moderna Announces European Union and European Economic Area Countries to Donate More than 70 Million Doses of Moderna COVID-19 Vaccine to COVAX in 2021 to Help End COVID-19 Pandemic in Low Income Countries
2021-11-15 14:35 ET
Health Canada Authorizes Booster Dose of Moderna’s COVID-19 Vaccine in Individuals 18 Years of Age and Older
2021-11-15 13:35 ET
Moderna Announces Positive Data from Phase 2 Study of mRNA VEGF-A Therapeutic in Patients Undergoing Coronary Artery Bypass Grafting Surgery
2021-11-12 22:23 ET
Moderna Announces Presentation of Interim Data from Phase 1 Study of mRNA Triplet Program at 2021 SITC Annual Meeting
2021-11-09 13:32 ET
Moderna Files to Expand the Conditional Marketing Authorization for its COVID-19 Vaccine in the European Union to Include Children Ages 6-11 Years
2021-11-04 11:00 ET
Moderna Reports Third Quarter Fiscal Year 2021 Financial Results and Provides Business Updates
2021-11-02 11:00 ET
Moderna and Metagenomi Establish Collaboration to Develop Next-Generation In Vivo Gene Editing Therapeutics
2021-11-01 11:00 ET
Moderna Announces Pledge to Achieve Net-Zero Carbon Emissions Globally by 2030
2021-10-31 14:00 ET
Moderna Provides Update on Timing of U.S. Emergency Use Authorization of its COVID-19 Vaccine for Adolescents
2021-10-29 14:15 ET
Moderna Announces Additional Supply for Q2 2022 of Vaccine for COVAX To Help End COVID-19 Pandemic in Lowest Income Countries
2021-10-28 20:01 ET
Moderna to Present at Upcoming Investor Conferences in November 2021
2021-10-28 18:20 ET
Moderna Named a Top Employer by Science for Seventh Consecutive Year
2021-10-26 18:38 ET
Moderna Announces First Participant Dosed in Phase 3 Pivotal Registration Study of Its mRNA Cytomegalovirus (CMV) Vaccine
2021-10-26 13:44 ET
Moderna Announces Swissmedic Authorizes Booster Dose of Moderna’s COVID-19 Vaccine
2021-10-26 05:23 ET
Moderna Announces Memorandum of Understanding to Supply up to 110 Million Doses of Its COVID-19 Vaccine to the African Union
2021-10-25 20:52 ET
Moderna Announces European Medicines Agency’s Committee for Medicinal Products for Human Use Recommends Booster Dose of Moderna’s COVID-19 Vaccine in the European Union
2021-10-25 12:30 ET
Moderna Announces Positive Top Line Data from Phase 2/3 Study of COVID-19 Vaccine in Children 6 to 11 Years of Age
2021-10-21 21:49 ET
U.S. CDC Advisory Committee on Immunization Practices Recommends Booster Vaccination with Moderna’s COVID-19 Vaccine
2021-10-20 21:37 ET
Moderna Announces FDA Authorization of a Booster Dose of Moderna’s COVID-19 Vaccine in the U.S.
2021-10-14 20:47 ET
Moderna Announces FDA Advisory Committee Unanimously Votes in Support of Emergency Use for a Booster Dose of Moderna’s COVID-19 Vaccine in the U.S.
2021-10-14 12:00 ET
Moderna to Report Third Quarter Financial Results on Thursday, November 4, 2021
2021-10-12 13:07 ET
Moderna Announces COVAX Exercises Option to Purchase 176.5 Million Additional Doses of Moderna’s COVID-19 Vaccine for Low Income Countries in First Half of 2022
2021-10-07 06:00 ET
Moderna to Build State-of-the-Art mRNA Facility in Africa to Manufacture up to 500 Million Doses Per Year
2021-10-06 12:30 ET
Moderna Announces the Launch of Global Fellowship Program for Young Researchers Exploring mRNA Medicines
2021-10-05 13:21 ET
Moderna Announces European Medicines Agency Authorizes Third Dose of COVID-19 Vaccine for Immunocompromised Individuals Aged 12 Years and Older
2021-09-30 12:07 ET
Moderna to Invest in New Science Center in Cambridge, MA
2021-09-28 12:18 ET
Moderna to Present at Chardan’s Virtual 5th Annual Genetic Medicines Conference
2021-09-24 13:40 ET
Moderna Announces Supply Agreement with Peru for 20 Million Doses of Its COVID-19 Vaccine
2021-09-16 16:13 ET
Moderna Announces Health Canada Approves its COVID-19 Vaccine
2021-09-15 20:00 ET
Moderna Highlights New Clinical Data on its COVID-19 Vaccine
2021-09-09 11:12 ET
Moderna Announces Significant Advances Across Industry-Leading mRNA Portfolio at 2021 R&D Day
2021-09-08 12:05 ET
Resilience to Manufacture mRNA for Moderna’s COVID-19 Vaccine
2021-09-07 12:30 ET
Moderna and the Institute for Life Changing Medicines Announce a New Collaboration to Develop an mRNA Therapeutic for Ultra-Rare Disease, Crigler-Najjar Syndrome Type 1
2021-09-03 20:01 ET
Moderna Announces Submission of Data to European Medicines Agency for its COVID-19 Vaccine Booster
2021-09-02 20:18 ET
Moderna to Present at Upcoming Investor Conferences in September 2021
2021-09-01 20:32 ET
Moderna Announces Submission of Initial Data to U.S. FDA for Its COVID-19 Vaccine Booster
2021-08-25 13:44 ET
Moderna Completes Submission of Biologics License Application to the U.S. Food and Drug Administration for its COVID-19 Vaccine
2021-08-24 20:25 ET
Moderna to Host Virtual R&D Day on Thursday, September 9, 2021
2021-08-18 12:05 ET
Azzur Group and Moderna Expand Their Ongoing Relationship
2021-08-16 13:30 ET
Moderna Announces Supply Agreement with Canada for Expanded Supply of Moderna’s COVID-19 Vaccine in 2022, in 2023 and in 2024
2021-08-16 12:57 ET
Moderna Announces First Patient Dosed in Phase 1/2 Study of mRNA-3705 for Methylmalonic Acidemia
2021-08-13 13:05 ET
Moderna Announces FDA Authorization of Third Dose of COVID-19 Vaccine for Immunocompromised Individuals
2021-08-12 21:03 ET
Moderna Announces New Study Showing Its COVID-19 Vaccine Maintains Antibodies Against Variants of Concern and Interest to 6 Months
2021-08-10 14:18 ET
Moderna and Canada Announce Collaboration to Bring mRNA Manufacturing to Canada
2021-08-09 14:05 ET
Australian Therapeutic Goods Administration Grants Provisional Registration for Moderna’s COVID-19 Vaccine
2021-08-06 11:44 ET
Moderna Named Fast Company’s 2021 Best Workplace for Innovators
2021-08-05 10:29 ET
Moderna Reports Second Quarter Fiscal Year 2021 Financial Results and Provides Business Updates
2021-08-03 13:10 ET
Moderna Receives FDA Fast Track Designation for Respiratory Syncytial Virus (RSV) Vaccine (mRNA-1345)
2021-08-02 12:44 ET
Moderna Announces First Participant Dosed in Phase 1 Study of Its IL-2 mRNA Therapeutic
2021-07-23 13:06 ET
EMA Committee for Medicinal Products for Human Use (CHMP) Adopts Positive Opinion Recommending Authorization for the Use of the Moderna COVID-19 Vaccine in Adolescents (12-17 Years of Age) in the European Union
2021-07-22 20:30 ET
Moderna Announces Establishment of New Charitable Foundation
2021-07-22 12:59 ET
Moderna Announces New Supply Agreement with Taiwan for 20 Million Doses of Moderna’s COVID-19 Vaccine and Variant Booster Vaccine Candidate in 2022 and 15 Million Doses in 2023
2021-07-20 10:42 ET
Moderna Partners with Takeda and the Government of Japan to Supply Additional 50 Million Doses of Moderna’s COVID-19 Vaccine and Variant Booster Vaccine Candidate in 2022
2021-07-15 23:01 ET
Moderna Set to Join S&P 500
2021-07-15 12:00 ET
Moderna to Report Second Quarter Financial Results on Thursday, August 5, 2021
2021-07-12 13:44 ET
Moderna Announces Supply Agreement with Argentina for 20 Million Doses of its COVID-19 Vaccine
2021-07-07 12:39 ET
Moderna Announces First Participant Dosed in Phase 1/2 Study of Its Quadrivalent Seasonal Flu mRNA Vaccine
2021-07-01 13:33 ET
Moderna Announces Recipharm Site in France Manufacturing COVID-19 Vaccine Moderna Following Approval by European Medicines Agency
2021-06-29 18:01 ET
Pfizer Vs Moderna Vs Johnson & Johnson
2021-06-29 13:59 ET
Moderna Announces Emergency Use Authorization for its COVID-19 Vaccine Granted by Government of India
2021-06-29 12:50 ET
Moderna Provides a Clinical Update on the Neutralizing Activity of its COVID-19 Vaccine on Emerging Variants Including the Delta Variant First Identified in India
2021-06-28 12:00 ET
Kate Cronin to Join Moderna as Chief Brand Officer on July 12
2021-06-22 13:06 ET
European Commission Purchases Additional 150 Million Doses of Moderna’s COVID-19 Vaccine for Delivery in 2022
2021-06-18 11:01 ET
Moderna Reaffirms Commitment to Job Creation in Massachusetts
2021-06-16 12:00 ET
U.S. Government Purchases Additional 200 Million Doses of Moderna’s COVID-19 Vaccine
2021-06-15 13:43 ET
Moderna and Magenta Partner to Distribute Moderna’s COVID-19 Vaccine and Updated Variant Booster Candidates in United Arab Emirates
2021-06-14 20:45 ET
Rafael Holdings Appoints Three Highly Experienced Biopharmaceutical Leaders to its Board of Directors
2021-06-14 12:10 ET
Dr. Paul Burton to Join Moderna as Chief Medical Officer
2021-06-14 11:07 ET
Moderna Submits Authorization Application for its COVID-19 Vaccine in Adolescents in Switzerland
2021-06-11 12:30 ET
Moderna and Tabuk Pharmaceuticals Partner to Commercialize Moderna’s COVID-19 Vaccine in Saudi Arabia
2021-06-10 12:00 ET
Moderna Files for Emergency Use Authorization for its COVID-19 Vaccine in Adolescents in the United States
2021-06-07 12:00 ET
Moderna and Medison Pharma Partner to Commercialize Moderna’s COVID-19 Vaccine Across Central Eastern Europe and Israel
2021-06-07 11:49 ET
Moderna Files for Authorization with Health Canada for its COVID-19 Vaccine in Adolescents
2021-06-07 11:40 ET
Moderna Files for Conditional Marketing Approval for its COVID-19 Vaccine in Adolescents in the European Union
2021-06-03 13:21 ET
Moderna Announces Agreement to Supply the Republic of Botswana with its COVID-19 Vaccine
2021-06-02 11:08 ET
UNICEF and Moderna Announce Long Term Agreement to Supply Vaccine on Behalf of the COVAX Facility
2021-06-02 05:00 ET
Moderna Announces New Drug Substance Production Agreement with Lonza in the Netherlands
2021-06-01 20:01 ET
Moderna Announces Agreement with Thermo Fisher Scientific for Fill/Finish Manufacturing of Moderna’s COVID-19 Vaccine
2021-06-01 11:30 ET
Moderna Announces Initiation of Rolling Submission of Biologics License Application (BLA) with U.S. FDA for the Moderna COVID-19 Vaccine
2021-05-28 12:00 ET
Moderna to Present at Upcoming Investor Conferences in June 2021
2021-05-27 11:40 ET
Moderna Highlights Advances in Platform Science and Innovative Vaccine Research at Fourth Annual Science Day
2021-05-25 12:00 ET
Moderna Announces TeenCOVE Study of its COVID-19 Vaccine in Adolescents Meets Primary Endpoint and Plans to Submit Data to Regulators in Early June
2021-05-24 11:00 ET
Moderna and Aldevron Announce Expanded Partnership for mRNA Vaccine and Therapeutic Pipeline
2021-05-22 16:00 ET
Moderna and Samsung Biologics Announce Agreement for Fill-Finish Manufacturing of Moderna's COVID-19 Vaccine
2021-05-22 16:00 ET
Moderna and Samsung Biologics Announce Agreement for Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine
2021-05-22 15:04 ET
Moderna and South Korea Explore Collaboration on mRNA Vaccines
2021-05-21 13:48 ET
Ministry of Food and Drug Safety of South Korea (MFDS) Authorizes Moderna’s COVID-19 Vaccine
2021-05-21 04:35 ET
Japan’s Ministry of Health, Labour and Welfare (MHLW) Approves Moderna’s COVID-19 Vaccine
2021-05-19 20:53 ET
Moderna to Host Fourth Annual Science Day on May 27, 2021
2021-05-19 12:37 ET
Moderna to Establish an International Business Services Hub in Warsaw, Poland
2021-05-12 11:00 ET
Moderna Announces New Supply Agreement with Australia for 25 Million Doses of its COVID-19 Vaccine
2021-05-07 13:13 ET
Moderna to Present at the Bank of America 2021 Healthcare Conference
2021-05-06 11:03 ET
Moderna Reports First Quarter Fiscal Year 2021 Financial Results and Provides Business Updates
2021-05-06 10:00 ET
Moderna Announces New Supply Agreement with Switzerland for 7 Million Booster Vaccine Doses in 2022 and Option for Additional 7 Million Doses
2021-05-05 20:01 ET
Moderna Announces Positive Initial Booster Data Against SARS-CoV-2 Variants of Concern
2021-05-04 12:08 ET
Moderna Announces Expansion of its Manufacturing Technology Center in Massachusetts
2021-05-03 10:00 ET
Moderna Announces Supply Agreement with Gavi for up to 500 Million Doses of COVID-19 Vaccine Moderna for COVAX To Help End COVID-19 Pandemic in Lowest Income Countries
2021-04-30 21:55 ET
Moderna Announces Emergency Use Listing Granted by the World Health Organization for its COVID-19 Vaccine
2021-04-29 05:00 ET
Moderna Announces Additional Investments to Increase Global Supply for COVID-19 Vaccine to up to 3 Billion Doses in 2022
2021-04-27 11:00 ET
DNA Script Partners with Moderna to Develop On-Demand Vaccines and Therapeutics for DARPA
2021-04-26 11:00 ET
Moderna Announces Agreement with Sanofi for Fill/Finish Manufacturing of the Moderna COVID-19 Vaccine in the U.S.
2021-04-20 20:25 ET
Moderna Announces New Supply Agreement with Israel for 2022
2021-04-16 12:59 ET
Moderna to Report First Quarter Financial Results on Thursday, May 6, 2021
2021-04-14 10:45 ET
Moderna Announces Clinical Progress from its Industry-Leading mRNA Vaccine Franchise and Continues Investments to Accelerate Pipeline Development
2021-04-13 20:29 ET
Moderna Provides Clinical and Supply Updates on COVID-19 Vaccine Program Ahead of 2nd Annual Vaccines Day
2021-04-09 12:00 ET
Moderna to Present at the 20th Annual Needham Virtual Healthcare Conference
2021-04-07 23:27 ET
Moderna Highlights Publication of Antibody Persistence Data of its COVID-19 Vaccine out to 6 Months in the New England Journal of Medicine
2021-04-06 13:00 ET
Moderna and Catalent Announce Long-Term Strategic Collaboration for Dedicated Vial Filling of Moderna’s COVID-19 Vaccine and Clinical Portfolio
2021-04-02 01:45 ET
Moderna Provides Storage Update & Announces the U.S. FDA Authorizes Up To 15-Doses Per Vial of its COVID-19 Vaccine
2021-04-01 15:07 ET
Ximedica announces partnership with Moderna, Inc. (Nasdaq: MRNA) to develop a prototype for rapid mobile manufacturing of vaccines
2021-03-31 12:00 ET
Moderna to Host Second Annual Virtual Vaccines Day on April 14, 2021
2021-03-29 12:05 ET
Moderna Announces Shipment of 100 Millionth Dose of its COVID-19 Vaccine to the U.S. Government
2021-03-22 13:25 ET
Moderna Announces New Supply Agreement with the Philippines for 7 Million Additional Doses of COVID-19 Vaccine Moderna
2021-03-16 10:59 ET
Moderna Announces First Participants Dosed in Phase 2/3 Study of COVID-19 Vaccine Candidate in Pediatric Population
2021-03-15 13:31 ET
First Participants Dosed in Phase 1 Study Evaluating mRNA-1283, Moderna’s Next Generation COVID-19 Vaccine
2021-03-10 21:30 ET
Dr. Elizabeth Nabel Rejoins Moderna’s Board of Directors
2021-03-10 21:09 ET
Moderna Announces First Participants Dosed in Study Evaluating COVID-19 Booster Vaccine Candidates
2021-03-09 12:54 ET
Moderna Named Fast Company’s Most Innovative Company for 2021
2021-03-08 14:00 ET
Baxter BioPharma Solutions and Moderna Announce Agreement for Fill/Finish Manufacturing of the Moderna COVID-19 Vaccine in the U.S.
2021-03-08 12:00 ET
Shannon Thyme Klinger Joins Moderna as Chief Legal Officer and Corporate Secretary
2021-03-06 17:23 ET
Moderna Announces Supply Agreement to Provide 13 Million Doses of COVID-19 Vaccine Moderna to the Philippines
2021-03-05 06:30 ET
Moderna Announces New Drug Application Submitted to Import and Distribute Moderna’s COVID-19 Vaccine Candidate in Japan
2021-03-04 16:15 ET
Moderna and IBM Plan to Collaborate on COVID-19 Vaccine Supply Chain and Distribution Data Sharing
2021-02-25 12:00 ET
Moderna Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Provides Business Updates
2021-02-24 21:30 ET
Moderna Announces Additional Capital Investments to Increase Global Manufacturing Capacity for COVID-19 Vaccine
2021-02-24 21:17 ET
Moderna Announces it has Shipped Variant-Specific Vaccine Candidate, mRNA-1273.351, to NIH for Clinical Study
2021-02-23 14:31 ET
Thinking about trading options or stock in Las Vegas Sands, Moderna, 3M, Five9, or MAG Silver?
2021-02-18 13:00 ET
Moderna to Present at Upcoming Investor Conferences in February and March 2021
2021-02-17 12:12 ET
European Commission Purchases Additional 150 Million Doses of COVID-19 Vaccine Moderna
2021-02-16 14:00 ET
Moderna Provides U.S. COVID-19 Vaccine Supply Update
2021-02-12 18:54 ET
Canada Purchases Additional 4 Million Doses of Moderna’s COVID-19 Vaccine
2021-02-11 22:03 ET
U.S. Government Purchases Additional 100 Million Doses of Moderna’s COVID-19 Vaccine
2021-02-11 14:47 ET
Qatar Ministry of Public Health Issues Emergency Use Authorization for COVID-19 Vaccine Moderna
2021-02-09 23:15 ET
Moderna Announces COVID-19 Vaccine Supply Agreements with the Government of Taiwan for 5 Million Doses and the Government of Colombia for 10 Million Doses
2021-02-04 13:00 ET
Moderna to Report Fourth Quarter and Full Year 2020 Financial Results on Thursday, February 25, 2021
2021-02-03 14:25 ET
Singapore Health Sciences Authority (HSA) Approves Interim Authorization of COVID-19 Vaccine Moderna For Use
2021-02-03 13:42 ET
Moderna Announces Amendment to Supply Agreement with Switzerland for an Additional 6 Million Doses of COVID-19 Vaccine Moderna
2021-01-27 13:20 ET
Moderna Confirms Discussions with U.S. Government for Additional 100 Million Doses of the Moderna COVID-19 Vaccine
2021-01-26 13:04 ET
Moderna Provides U.S. COVID-19 Vaccine Supply Update
2021-01-25 17:49 ET
Moderna to Host Conference Call on COVID-19 Variants Announcement on Monday, Jan. 25
2021-01-25 13:28 ET
Moderna COVID-19 Vaccine Retains Neutralizing Activity Against Emerging Variants First Identified in the U.K. and the Republic of South Africa
2021-01-21 14:00 ET
Moderna Announces First Participant Dosed in Phase 1/2 Study of Moderna COVID-19 Vaccine in Japan Led by Takeda
2021-01-12 13:00 ET
Uber and Moderna Collaborate to Raise Awareness and Increase Access to COVID-19 Vaccines
2021-01-12 13:00 ET
José M. Vega, M.D. Joins Moderna as Chief Safety Officer
2021-01-12 12:59 ET
Swissmedic Authorizes COVID-19 Vaccine Moderna for Use in Switzerland
2021-01-11 12:20 ET
Moderna Provides Business Update and Announces Three New Development Programs in Infectious Disease Vaccines
2021-01-08 12:46 ET
United Kingdom Medicines and Healthcare products Regulatory Agency Authorizes Use of COVID-19 Vaccine Moderna
2021-01-07 13:00 ET
Corinne Le Goff, Pharm.D. Will Join Moderna as Chief Commercial Officer on January 19
2021-01-06 16:09 ET
European Commission Authorizes COVID-19 Vaccine Moderna in Europe
2021-01-04 23:58 ET
Israeli Ministry of Health Authorizes COVID-19 Vaccine Moderna for Use in Israel
2021-01-04 14:15 ET
Moderna Provides COVID-19 Vaccine Supply Update
2021-01-04 12:00 ET
Moderna to Provide Business and Pipeline Updates at the 2021 J.P. Morgan Healthcare Conference
2020-12-31 14:22 ET
Moderna Announces Publication of Results from the Pivotal Phase 3 Trial of the Moderna COVID-19 Vaccine in The New England Journal of Medicine
2020-12-31 14:14 ET
Moderna Confirms 40 Million COVID-19 Vaccine Dose Supply Agreement with the Government of the Republic of Korea
2020-12-30 16:28 ET
Recipharm and Moderna Finalize Agreement for Aseptic Drug Product Manufacturing and Fill-Finish for Supply to Countries Outside the U.S.
2020-12-29 21:08 ET
Moderna Confirms Discussions With the Government of South Korea to Supply South Korea With 40 Million Doses of COVID-19 Vaccine
2020-12-29 13:00 ET
Moderna to Present at the Goldman Sachs 13th Annual Healthcare CEOs Unscripted Conference: A View from the Top
2020-12-23 16:20 ET
Health Canada Authorizes Moderna COVID-19 Vaccine in Canada
2020-12-20 02:44 ET
U.S. CDC Advisory Committee on Immunization Practices Recommends Vaccination with Moderna’s COVID-19 Vaccine for Persons 18 Years and Older
2020-12-19 00:46 ET
Moderna Announces FDA Authorization of Moderna COVID-19 Vaccine in U.S.
2020-12-18 13:00 ET
European Commission Exercises Option for Additional 80 Million Doses of Moderna’s COVID-19 Vaccine Candidate
2020-12-17 22:27 ET
Moderna Receives FDA Advisory Committee Vote Supporting Emergency Use for Moderna’s Vaccine Against COVID-19 in the United States
2020-12-14 14:31 ET
Moderna Confirms Supply Agreement with the Ministry of Health to Supply Singapore with mRNA Vaccine Against COVID-19 (mRNA-1273)
2020-12-11 21:30 ET
U.S. Government Exercises 1st Option for Additional 100 Million Doses of Moderna’s COVID-19 Vaccine Candidate
2020-12-10 12:00 ET
Moderna Announces First Participants Dosed in Phase 2/3 Study of COVID-19 Vaccine Candidate in Adolescents
2020-12-09 13:30 ET
Soligenix, Inc. COVID-19 Vaccine Candidate, CiVax, Could Be a More Viable Alternative to Moderna and Pfizer
2020-12-08 13:00 ET
Switzerland Exercises Increased Option for 7.5 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273)
2020-12-07 14:27 ET
Canada Exercises Increased Option for Total of 40 Million Doses of mRNA Vaccine Candidate Against COVID-19 (mRNA-1273)
2020-12-04 13:27 ET
Moderna Announces Amendment to Supply Agreement with the Ministry of Health of Israel to Supply Additional Doses of mRNA Vaccine Against COVID-19 (mRNA-1273)
2020-12-03 22:07 ET
Moderna Provides Updates on the Clinical Development and Production of Its COVID-19 Vaccine Candidate
2020-11-30 11:59 ET
Moderna Announces Primary Efficacy Analysis in Phase 3 COVE Study for Its COVID-19 Vaccine Candidate and Filing Today with U.S. FDA for Emergency Use Authorization
2020-11-29 13:37 ET
Moderna Announces Amendment to Current Supply Agreement with United Kingdom Government for an Additional 2 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273)
2020-11-27 18:01 ET
Moderna to Present at Upcoming Investor Conferences in December 2020
2020-11-25 11:49 ET
Moderna Announces the European Commission’s Approval of Advance Purchase Agreement for Initial 80 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273)
2020-11-17 14:18 ET
European Medicines Agency Begins Rolling Review of Moderna’s mRNA Vaccine Candidate Against COVID-19 (mRNA-1273)
2020-11-17 14:11 ET
Moderna Announces Supply Agreement with United Kingdom Government to Supply mRNA Vaccine Against COVID-19 (mRNA-1273) if Approved for Use
2020-11-17 13:00 ET
Pfizer and Moderna COVID-19 Vaccine Candidates Are Promising, but Soligenix's Civax (TM) May Be a Better Alternative
2020-11-16 11:56 ET
Moderna’s COVID-19 Vaccine Candidate Meets its Primary Efficacy Endpoint in the First Interim Analysis of the Phase 3 COVE Study
2020-11-16 11:52 ET
Moderna Announces Longer Shelf Life for its COVID-19 Vaccine Candidate at Refrigerated Temperatures
2020-11-13 12:18 ET
Swissmedic Begins Rolling Review of Moderna’s mRNA Vaccine Against COVID-19 (mRNA-1273)
2020-11-11 21:01 ET
Moderna Has Completed Case Accrual for First Planned Interim Analysis of its mRNA Vaccine Against COVID-19 (mRNA-1273)
2020-11-11 12:09 ET
Moderna Announces Clinical Updates on Personalized Cancer Vaccine Program
2020-11-02 13:33 ET
Moderna to Present at Upcoming Investor Conferences in November 2020
2020-10-30 13:29 ET
Moderna Named Top Employer by Science for Sixth Consecutive Year
2020-10-29 11:00 ET
Moderna Reports Third Quarter 2020 Financial Results and Provides Business Updates
2020-10-29 06:00 ET
Moderna Partners with Takeda and the Government of Japan to Supply 50 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273) to Japan
2020-10-27 13:00 ET
UK Medicines and Healthcare products Regulatory Agency Begins Rolling Review of Moderna’s mRNA Vaccine Against COVID-19 (mRNA-1273)
2020-10-26 11:00 ET
Moderna Announces Supply Agreement with the Ministry of Public Health to Supply Qatar with mRNA Vaccine Against COVID-19 (mRNA-1273)
2020-10-22 13:47 ET
Moderna Completes Enrollment of Phase 3 COVE Study of mRNA Vaccine Against COVID-19 (mRNA-1273)
2020-10-19 14:00 ET
2nd Annual Gabelli Funds – Columbia Business School Healthcare Symposium (Virtual)
2020-10-15 20:15 ET
Moderna to Report Third Quarter 2020 Financial Results on Thursday, October 29, 2020
2020-10-14 12:00 ET
Moderna Receives Confirmation of Eligibility for Submission of Marketing Authorization Application to the European Medicines Agency for mRNA Vaccine Against COVID-19 (mRNA-1273)
2020-10-13 15:04 ET
Moderna Announces Initiation of Rolling Submission to Health Canada for mRNA Vaccine Against COVID-19 (mRNA-1273)
2020-10-08 10:50 ET
DARPA Awards Moderna up to $56 Million to Enable Small-Scale, Rapid Mobile Manufacturing of Nucleic Acid Vaccines and Therapeutics
2020-10-08 10:45 ET
Moderna Announces Updates on Respiratory Syncytial Virus (RSV) Vaccine Program
2020-09-29 22:17 ET
Moderna Announces Publication in The New England Journal of Medicine of Interim Results From Older Adult Age Cohorts in Phase 1 Study of its mRNA Vaccine Against COVID-19 (mRNA-1273)
2020-09-28 13:00 ET
Moderna to Present at the Chardan Virtual 4th Annual Genetic Medicines Conference
2020-09-22 16:22 ET
Canada Exercises Increased Option for 20 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273)
2020-09-17 10:59 ET
Moderna Announces Progress Across Broad Portfolio and all Three Clinical Stage Therapeutic Areas at 2020 R&D Day
2020-09-16 20:30 ET
Moderna and Vertex Establish New Collaboration to Treat Cystic Fibrosis Using Gene Editing
2020-09-16 20:01 ET
Moderna and Chiesi Group Establish Collaboration to Discover and Develop mRNA Therapeutics for Pulmonary Arterial Hypertension (PAH)
2020-09-16 09:00 ET
Moderna Announces First Commercial Organization Outside North America in Switzerland
2020-09-10 12:00 ET
Moderna Names Michael Mullette as Managing Director of New Canadian Subsidiary
2020-09-09 12:15 ET
Moderna to Present at Upcoming Investor Conferences in September 2020
2020-09-03 12:00 ET
Moderna to Host Virtual R&D Day on September 17, 2020
2020-08-28 10:19 ET
Moderna Confirms Discussions with the Ministry of Health, Labour and Welfare to Supply Japan with 40 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273)
2020-08-26 12:53 ET
Moderna to Present New Interim Clinical Data About mRNA Vaccine Against COVID-19 (mRNA-1273) at Advisory Committee on Immunization Practices (ACIP) Meeting
2020-08-24 13:18 ET
Moderna Confirms Advanced Discussions with European Commission to Supply Europe with 80 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273)
2020-08-11 21:49 ET
Moderna Announces Supply Agreement with U.S. Government for Initial 100 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273)
2020-08-10 20:05 ET
John Lepore Joins Moderna as Senior Vice President, Government Engagement
2020-08-05 20:05 ET
AWS Powers Moderna’s Digital Biotechnology Platform to Develop New Class of Vaccines and Therapeutics
2020-08-05 11:00 ET
Moderna Reports Second Quarter 2020 Financial Results and Provides Business Updates
2020-08-03 13:00 ET
Indigo Ag Announces an Additional $360M in Financing, Appoints Stéphane Bancel, Moderna CEO, to Board of Directors
2020-07-30 20:27 ET
Moderna Announces Resignation of Dr. Elizabeth Nabel From Board of Directors
2020-07-28 19:23 ET
Moderna Announces Publication in The New England Journal of Medicine of Non-Human Primate Preclinical Viral Challenge Study of its mRNA Vaccine Against COVID-19 (mRNA-1273)
2020-07-27 10:52 ET
Moderna Announces Phase 3 COVE Study of mRNA Vaccine Against COVID-19 (mRNA-1273) Begins
2020-07-26 14:22 ET
Moderna Announces Expansion of BARDA Agreement to Support Larger Phase 3 Program for Vaccine (mRNA-1273) Against COVID-19
2020-07-24 19:53 ET
Statement from Moderna on Patent Trial and Appeal Board (PTAB) Ruling
2020-07-23 05:00 ET
Medidata Supports Moderna’s COVID-19 Vaccine Clinical Trials with Rave Clinical Cloud Platform
2020-07-22 12:00 ET
Moderna to Report Second Quarter 2020 Financial Results on Wednesday, August 5, 2020
2020-07-14 21:14 ET
Moderna Announces Publication in The New England Journal of Medicine of Interim Results From Phase 1 Study of Its mRNA Vaccine Against COVID-19 (mRNA-1273)
2020-07-14 13:06 ET
Moderna to Join the NASDAQ-100 Index Beginning July 20, 2020
2020-07-13 14:33 ET
Moderna, Inc. to Join the NASDAQ-100 Index Beginning July 20, 2020
2020-07-09 12:00 ET
Moderna and ROVI Announce Collaboration for OUS Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine Candidate
2020-07-08 13:44 ET
Moderna Completes Enrollment of Phase 2 Study of its mRNA Vaccine Against COVID-19 (mRNA-1273)
2020-07-01 12:00 ET
Elizabeth Tallett Joins Moderna’s Board of Directors
2020-06-16 12:00 ET
Moderna to Present at BMO 2020 Prescriptions for Success Healthcare Conference
2020-06-15 12:00 ET
Ray Jordan Joins Moderna as Chief Corporate Affairs Officer
2020-06-11 11:57 ET
Moderna Advances Late-Stage Development of its Vaccine (mRNA-1273) Against COVID-19
2020-06-04 12:00 ET
David Meline Joins Moderna as Chief Financial Officer
2020-06-02 11:30 ET
Moderna Highlights Advances in Platform Science and Innovative Vaccine Research at Third Annual Science Day
2020-05-29 20:52 ET
Moderna Announces First Participants in Each Age Cohort Dosed in Phase 2 Study of mRNA Vaccine (mRNA-1273) Against Novel Coronavirus
2020-05-27 12:00 ET
Moderna to Present at Upcoming Investor Conferences
2020-05-26 12:00 ET
Moderna to Host Virtual Science Day on June 2, 2020
2020-05-19 02:32 ET
Moderna Announces Pricing of Public Offering of Shares of Common Stock
2020-05-18 20:18 ET
Moderna Announces Proposed Public Offering of Shares of Common Stock
2020-05-18 11:30 ET
Moderna Announces Positive Interim Phase 1 Data for its mRNA Vaccine (mRNA-1273) Against Novel Coronavirus
2020-05-15 16:53 ET
Moderna Congratulates Dr. Moncef Slaoui on His Appointment to Oversee the White House’s Operation Warp Speed Initiative
2020-05-12 12:00 ET
Moderna Receives FDA Fast Track Designation for mRNA Vaccine (mRNA-1273) Against Novel Coronavirus
2020-05-08 12:04 ET
Moderna to Present at Upcoming Investor Conferences
2020-05-07 11:00 ET
Moderna Reports First Quarter 2020 Financial Results and Provides Business Updates
2020-05-01 04:50 ET
Moderna and Lonza Announce Worldwide Strategic Collaboration to Manufacture Moderna’s Vaccine (mRNA-1273) Against Novel Coronavirus
2020-04-27 20:30 ET
Moderna Announces IND Submitted to U.S. FDA for Phase 2 Study of mRNA Vaccine (mRNA-1273) Against Novel Coronavirus
2020-04-23 12:00 ET
Moderna to Report First Quarter 2020 Financial Results on Thursday, May 7th, 2020
2020-04-16 21:55 ET
Moderna Announces Award from U.S. Government Agency BARDA for up to $483 Million to Accelerate Development of mRNA Vaccine (mRNA-1273) Against Novel Coronavirus
2020-04-14 11:00 ET
Moderna Highlights Opportunity of mRNA Vaccines at its First Vaccines Day
2020-04-10 14:53 ET
Moderna Announces that Its 2020 Annual Meeting of Stockholders Will be Held in Virtual Format
2020-04-08 12:00 ET
Moderna to Present at 19th Annual Needham Healthcare Conference
2020-04-07 12:00 ET
Moderna to Host Virtual Vaccines Day on April 14, 2020
2020-03-30 00:48 ET
Moderna Provides Update on the Impact of COVID-19 on Business Operations and Clinical Program Development
2020-03-25 12:00 ET
Moderna to Present at MIT Lecture Series
2020-03-16 16:42 ET
Moderna Announces First Participant Dosed in NIH-led Phase 1 Study of mRNA Vaccine (mRNA-1273) Against Novel Coronavirus
2020-03-03 21:01 ET
Moderna Completes Enrollment of Cytomegalovirus (CMV) Vaccine (mRNA-1647) Phase 2 Study
2020-03-03 00:37 ET
Moderna Announces Updated Plans for its March 4 Manufacturing & Digital Day Event
2020-02-26 21:30 ET
Moderna to Host Manufacturing & Digital Day on March 4, 2020
2020-02-26 12:00 ET
Moderna Reports 2019 Fourth Quarter and Full Year Financial Results and Highlights Advancements in Core Modalities
2020-02-24 23:04 ET
Moderna Ships mRNA Vaccine Against Novel Coronavirus (mRNA-1273) for Phase 1 Study
2020-02-24 13:00 ET
Moderna to Present at Upcoming Investor Conferences
2020-02-12 21:30 ET
Moderna to Report Fourth Quarter and Full Year 2019 Financial Results on Wednesday, February 26th, 2020
2020-02-12 03:12 ET
Moderna Announces Pricing of Public Offering of Shares of Common Stock
2020-02-10 22:11 ET
Moderna Announces Progress in Prophylactic Vaccines Modality with CMV Vaccine Phase 2 Study Data Now Expected in Third Quarter 2020 and Expands Investment in This Core Modality with Three New Development Candidates
2020-02-10 22:10 ET
Moderna Announces First Patient Enrolled in Phase 1/2 Study of mRNA-3704 for Methylmalonic Acidemia
2020-02-10 21:13 ET
Moderna Announces Proposed Public Offering of Shares of Common Stock
2020-02-03 13:00 ET
Sandra Horning, M.D. To Join Moderna’s Board of Directors
2020-01-30 13:00 ET
Melanie Ivarsson, Ph.D. Joins Moderna as Chief Development Officer
2020-01-23 14:15 ET
Moderna Announces Funding Award from CEPI to Accelerate Development of Messenger RNA (mRNA) Vaccine Against Novel Coronavirus
2020-01-12 19:00 ET
Moderna Builds on Clinical Validation of Systemic Delivery with Two Additional Development Candidates in New Autoimmune Therapeutic Area
2020-01-09 21:01 ET
Moderna Announces Additional Positive Phase 1 Data from Cytomegalovirus (CMV) Vaccine (mRNA-1647) and First Participant Dosed in Phase 2 Study
2020-01-06 13:30 ET
Moderna to Provide Business and Pipeline Updates at the 2020 J.P. Morgan Healthcare Conference
2019-12-11 13:00 ET
Moderna Announces Key 2020 Investor and Analyst Events
2019-12-10 13:00 ET
François Nader, M.D., Joins Moderna’s Board of Directors
2019-11-26 13:00 ET
Moderna to Present at 31st Annual Piper Jaffray Healthcare Conference
2019-11-06 12:00 ET
Moderna Provides Business Updates and Reports Third Quarter 2019 Financial Results
2019-11-05 13:00 ET
Moderna to Present at Credit Suisse 28th Annual Healthcare Conference
2019-10-24 18:21 ET
Moderna Named Top Employer by Science for Fifth Consecutive Year
2019-10-22 20:15 ET
Moderna Receives FDA Fast Track Designation for Propionic Acidemia Program (mRNA-3927)
2019-10-22 12:00 ET
Moderna to Report Third Quarter 2019 Financial Results on Wednesday, November 6th, 2019
2019-10-02 11:00 ET
Moderna to Present Data From Two of Its Prophylactic mRNA Vaccines at IDWeek 2019
2019-09-30 12:00 ET
Moderna Announces Open IND for Propionic Acidemia Program (mRNA-3927)
2019-09-26 12:00 ET
Moderna Announces mRNA Immunotherapy Research Collaboration with Harvard University
2019-09-25 12:00 ET
Moderna to Present at Upcoming Investor Conferences
2019-09-12 10:31 ET
Moderna Announces Positive Phase 1 Results for the First Systemic Messenger RNA Therapeutic Encoding a Secreted Protein (mRNA-1944)
2019-09-12 10:30 ET
Moderna Announces Positive Interim Results from Phase 1 Cytomegalovirus (CMV) Vaccine (mRNA-1647) Study and Progress Toward Phase 2 and Pivotal Trials

SEC forms

Show financial reports only

SEC form 10
2025-02-21 00:00 ET
Moderna published news for 2024 q4
SEC form 8
2025-02-14 06:30 ET
Moderna reported for 2024 q4
SEC form 8
2025-02-14 06:30 ET
Moderna published news for 2024 q4
SEC form 8
2025-01-13 00:00 ET
Moderna published news for 2024 q4
SEC form 8
2025-01-13 00:00 ET
Moderna published news for 2024 q4
SEC form 10
2024-11-07 16:03 ET
Moderna reported for 2024 q3
SEC form 8
2024-11-07 06:33 ET
Moderna reported for 2024 q3
SEC form 8
2024-11-07 06:33 ET
Moderna published news for 2024 q3
SEC form 10
2024-08-01 16:02 ET
Moderna reported for 2024 q2
SEC form 8
2024-08-01 06:31 ET
Moderna reported for 2024 q2
SEC form 8
2024-08-01 06:31 ET
Moderna published news for 2024 q2
SEC form 10
2024-08-01 00:00 ET
Moderna reported for 2024 q2
SEC form 10
2024-05-02 16:03 ET
Moderna published news for 2024 q1
SEC form 8
2024-05-02 06:31 ET
Moderna reported for 2024 q1
SEC form 8
2024-05-02 06:31 ET
Moderna published news for 2024 q1
SEC form 10
2024-05-02 00:00 ET
Moderna published news for 2024 q1
SEC form 10
2024-02-23 16:03 ET
Moderna published news for 2023 q4
SEC form 10
2024-02-23 00:00 ET
Moderna published news for 2023 q4
SEC form 8
2024-02-22 06:32 ET
Moderna published news for 2023 q4
SEC form 8
2024-02-22 06:32 ET
Moderna reported for 2023 q4
SEC form 8
2024-01-08 00:00 ET
Moderna published news for 2023 q4
SEC form 8
2024-01-08 00:00 ET
Moderna published news for 2023 q4
SEC form 10
2023-11-03 16:02 ET
Moderna reported for 2023 q3
SEC form 10
2023-11-03 00:00 ET
Moderna reported for 2023 q3
SEC form 8
2023-11-02 06:33 ET
Moderna reported for 2023 q3
SEC form 10
2023-08-03 16:04 ET
Moderna reported for 2023 q2
SEC form 6
2023-08-03 06:33 ET
Moderna reported for 2023 q2
SEC form 10
2023-08-03 00:00 ET
Moderna reported for 2023 q2
SEC form 8
2023-08-03 00:00 ET
Moderna reported for 2023 q2
SEC form 10
2023-05-04 00:00 ET
Moderna published news for 2023 q1
SEC form 8
2023-05-04 00:00 ET
Moderna published news for 2023 q1
SEC form 10
2023-02-24 16:03 ET
Moderna reported for 2022 q4
SEC form 10
2023-02-24 00:00 ET
Moderna reported for 2022 q4
SEC form 6
2023-02-23 07:03 ET
Moderna published news for 2022 q4
SEC form 8
2023-02-23 00:00 ET
Moderna reported for 2022 q4
SEC form 6
2023-01-09 07:03 ET
Moderna published news for 2022 q4
SEC form 8
2023-01-09 00:00 ET
Moderna published news for 2022 q4
SEC form 6
2023-01-03 07:05 ET
Moderna published news for 2022 q4
SEC form 6
2022-12-13 07:06 ET
Moderna published news for 2022 q3
SEC form 10
2022-11-03 16:05 ET
Moderna reported for 2022 q3
SEC form 6
2022-11-03 07:04 ET
Moderna published news for 2022 q3
SEC form 10
2022-11-03 00:00 ET
Moderna reported for 2022 q3
SEC form 6
2022-09-29 08:08 ET
Moderna published news for 2022 q2
SEC form 6
2022-08-17 16:25 ET
Moderna published news for 2022 q2
SEC form 10
2022-08-03 16:01 ET
Moderna reported for 2022 q2
SEC form 6
2022-08-03 07:04 ET
Moderna published news for 2022 q2
SEC form 8
2022-08-03 00:00 ET
Moderna reported for 2022 q2
SEC form 10
2022-08-03 00:00 ET
Moderna reported for 2022 q2
SEC form 6
2022-06-01 16:31 ET
Moderna published news for 2022 q1
SEC form 6
2022-05-24 08:01 ET
Moderna published news for 2022 q1
SEC form 6
2022-05-13 16:05 ET
Moderna published news for 2022 q1
SEC form 6
2022-05-11 08:01 ET
Moderna published news for 2022 q1
SEC form 10
2022-05-04 16:07 ET
Moderna reported for 2022 q1
SEC form 6
2022-05-04 06:58 ET
Moderna published news for 2022 q1
SEC form 8
2022-05-04 00:00 ET
Moderna reported for 2022 q1
SEC form 10
2022-05-04 00:00 ET
Moderna reported for 2022 q1
SEC form 6
2022-05-03 16:36 ET
Moderna published news for 2022 q1
SEC form 6
2022-04-11 09:10 ET
Moderna published news for 2022 q1
SEC form 6
2022-03-09 16:16 ET
Moderna published news for 2021 q4
SEC form 10
2022-02-25 08:07 ET
Moderna published news for 2021 q4
SEC form 10
2022-02-25 00:00 ET
Moderna published news for 2021 q4
SEC form 6
2022-02-24 07:16 ET
Moderna published news for 2021 q4
SEC form 8
2022-02-24 00:00 ET
Moderna published news for 2021 q4
SEC form 6
2022-01-10 07:22 ET
Moderna published news for 2021 q4
SEC form 8
2022-01-10 00:00 ET
Moderna published news for 2021 q4
SEC form 6
2022-01-04 08:00 ET
Moderna published news for 2021 q4
SEC form 8
2022-01-04 00:00 ET
Moderna published news for 2021 q4
SEC form 10
2021-11-04 16:48 ET
Moderna published news for 2021 q3
SEC form 6
2021-11-04 07:04 ET
Moderna published news for 2021 q3
SEC form 10
2021-11-04 00:00 ET
Moderna published news for 2021 q3
SEC form 8
2021-11-04 00:00 ET
Moderna published news for 2021 q3
SEC form 10
2021-08-05 16:14 ET
Moderna published news for 2021 q2
SEC form 6
2021-08-05 06:42 ET
Moderna published news for 2021 q2
SEC form 8
2021-08-05 00:00 ET
Moderna published news for 2021 q2
SEC form 10
2021-08-05 00:00 ET
Moderna published news for 2021 q2
SEC form 10
2021-05-06 16:30 ET
Moderna published news for 2021 q1
SEC form 6
2021-05-06 07:29 ET
Moderna published news for 2021 q1
SEC form 8
2021-05-06 00:00 ET
Moderna published news for 2021 q1
SEC form 10
2021-05-06 00:00 ET
Moderna published news for 2021 q1
SEC form 6
2021-04-29 16:17 ET
Moderna published news for 2021 q1
SEC form 6
2021-04-28 07:33 ET
Moderna published news for 2021 q1
SEC form 6
2021-04-13 17:28 ET
Moderna published news for 2021 q1
SEC form 6
2021-04-13 10:41 ET
Moderna published news for 2021 q1
SEC form 8
2021-04-13 00:00 ET
Moderna published news for 2021 q1
SEC form 6
2021-03-10 16:39 ET
Moderna published news for 2020 q4
SEC form 6
2021-03-10 16:31 ET
Moderna published news for 2020 q4
SEC form 10
2021-02-26 16:30 ET
Moderna published news for 2020 q4
SEC form 6
2021-02-25 07:07 ET
Moderna published news for 2020 q4
SEC form 6
2021-01-04 08:06 ET
Moderna published news for 2020 q4
SEC form 6
2020-12-23 07:48 ET
Moderna published news for 2020 q3
SEC form 6
2020-12-21 07:03 ET
Moderna published news for 2020 q3
SEC form 6
2020-12-11 16:40 ET
Moderna published news for 2020 q3
SEC form 6
2020-11-30 07:04 ET
Moderna published news for 2020 q3
SEC form 6
2020-11-16 07:01 ET
Moderna published news for 2020 q3
SEC form 10
2020-10-30 08:24 ET
Moderna published news for 2020 q3
SEC form 6
2020-10-29 07:07 ET
Moderna published news for 2020 q3